Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-HOPE-001: IBI343 monotherapy versus investigator's choice in previously treated CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
CTR20240639Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of arcotatug tavatecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by InnoCare Pharma. Started Jun 2024; status: active.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20240639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240639.